SecBot SecBot
8-K ·Filed Apr 3, 2026

DNLI

Denali Therapeutics Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed7mo ago SEC0001714899-26-000042
8-K material event: Items 1.02
Actionable Insight • Neutral

Monitor Denali's upcoming Phase 1/2 data readout for DNL593 by end of 2026, which will be critical for validating the program's potential without Takeda's backing and determining future partnership or funding needs.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.38
T+0 close · Apr 3, 2026 · via day close
Latest settled
+34.06%
T+60 · $25.98
Vs SPY
+20.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $19.38entry
  2. T+1 · 7mo ago +0.15%α +0.09% · $19.41
  3. T+5 · 7mo ago +0.21%α −3.93% · $19.42
  4. T+20 · 7mo ago −3.66%α −12.65% · $18.67
  5. T+60 · 5mo ago +34.06%α +20.59% · $25.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Denali Therapeutics announced that Takeda has terminated their 2018 collaboration agreement to co-develop and co-commercialize DNL593 for frontotemporal dementia, citing strategic reasons unrelated to efficacy or safety. Denali will regain full rights to the program and continue its clinical development independently, with Phase 1/2 data expected by end of 2026.

Key Facts

  • Takeda terminated the 2018 collaboration agreement for DNL593 (PTV:PGRN) for FTD-GRN due to strategic considerations, not efficacy or safety issues
  • All rights to DNL593 will revert to Denali 60 days after the April 3, 2026 notice
  • Denali will have no further financial obligations to Takeda post-termination
  • Denali plans to continue clinical development of DNL593 independently
  • Data from the ongoing Phase 1/2 study in FTD-GRN patients is expected by end of 2026

Financial Impact

Loss of Takeda's financial support for DNL593 development; Denali assumes full funding responsibility

R&D expensescash flowdevelopment risk

Risk Factors

  • Increased financial burden on Denali to fund DNL593 development independently
  • Loss of Takeda's commercialization expertise and resources for a potential future launch
  • Clinical data expected in late 2026 may face delays or fail to meet efficacy endpoints

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001714899-26-000042
Exhibit: ex9912026pressrelease4326.htm0001714899-26-000042
Document: 0001714899-26-000042-index-headers.html0001714899-26-000042
Document: 0001714899-26-000042-index.html0001714899-26-000042
Document: 0001714899-26-000042.txt0001714899-26-000042

Track record

17 reports on DNLI

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
  2. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
  4. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
  6. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
  7. Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
  9. Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
  10. Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026